<span lang="EN-GB"></span> <font face="Times New Roman" size="3"> </font> <span lang="EN-GB"></span>

 

 

<span lang="EN-GB"></span>

Our vision is to be the accepted PAIONeer in sedation and anesthesia; helping advance patient care.

Our vision is to be the accepted PAIONeer in sedation and anesthesia; helping advance patient care.

Company

Company

Remimazolam

Remimazolam

Media and Investors

Media and Investors

PAION AG is a publicly listed specialty pharmaceutical company developing and aiming to commercialize innovative drugs for out-patient and hospital-based sedation, anesthesia and critical care services.

 

Learn more About PAION

news

10/22/2020

PAION Insights Newsletter October 2020

PAION Insights Newsletter October 2020

Read more
10/06/2020

PAION REPORTS PROGRESS WITH BYFAVO (REMIMAZOLAM) BY ITS LICENSEE ACACIA IN THE...

DGAP-News: PAION AG / Key word(s): Miscellaneous06.10.2020 /...

Read more
09/25/2020

Presentation Baader Investment Conference September 2020

Presentation Baader Investment Conference September 2020

Read more
To the newsroom

PAION Chart

Load Chart

I consent to the display of external content. This enables personal data to be transmitted to third-party platforms. Read more about our privacy policy.

 

Visit us on LinkedIn!
LinkedIn